Results 41 to 50 of about 536 (130)

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

Case Reports in Gastroenterology, 2017
Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b.
Kazuo Tarao, Kouzo Yamada
doaj   +1 more source

The demographic and clinical features of 278 patients with genotype 1b hepatitis C virus (HCV) infection receiving daclatasvir (DCV) plus asunaprevir (ASV) therapy.

, 2018
The demographic and clinical features of 278 patients with genotype 1b hepatitis C virus (HCV) infection receiving daclatasvir (DCV) plus asunaprevir (ASV) therapy.
Kayoko Sugawara (5848991), Yukinori Imai (5849006), Nobuaki Nakayama (5849003), Masamitsu Nakao (5848994), Mie Inao (5849000), Satoshi Mochida (156566), Jun-ichi Kouyama (661243), Daisuke Motoya (5848997), Yoshihito Uchida (661242), Kayoko Naiki (661244), Tomoaki Tomiya (479370)   +10 more
core   +1 more source

Small Molecule‐Based Conditional Gene Regulation: Advances and Applications

Chemistry–Methods, Volume 6, Issue 4, April 2026.
The precise, temporal, and reversible control of gene expression using small molecule ligands is crucial for understanding complex cellular functions and is rapidly advancing the field of synthetic biology. Small molecule‐mediated conditional gene regulation has widespread applications, including bio‐manufacturing, cellular reprogramming, gene therapy,
Mohd Afaque Ansari, Riddhima Sharma, Priyanka Swami, Ambadas B. Rode   +3 more
wiley   +1 more source

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. [PDF]

PLoS ONE, 2018
BACKGROUND:Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon-
Yun Lu, Xiuze Jin, Cheng-A-Xin Duan, Feng Chang   +3 more
doaj   +1 more source

The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
Abstract Mosquito‐borne flaviviruses are important human pathogenic viruses and can cause an array of symptoms ranging from asymptomatic to mild illness but can progress to severe disease conditions. Prominent members of the family Flaviviridae include Dengue virus, Zika virus, and West Nile virus, whose spread has increased globally due to the ...
Haejeong Lee, Hee Cho, Michaela U. Gack
wiley   +1 more source

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

, 2015
BACKGROUND & AIMS: Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this ...
Jensen, D., Hezode, C., Sherman, K. E., Elkhashab, M., Noviello, S., Zeuzem, S., Bernstein, D., +13 additional authors, de Ledinghen, V., Tran, A., Pol, S.   +10 more
core   +2 more sources

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target‐Bound

Chemistry – A European Journal, Volume 32, Issue 8, 23 February 2026.
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Lianne H. E. Wieske, Guanhong Bu, Máté Erdélyi, Jan Kihlberg, Tamir Gonen, Emma Rova Danelius   +5 more
wiley   +1 more source

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats

Pharmaceutics, 2023
Gadoxetate, a magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-anion-transporting polypeptide 1B1 and multidrug resistance-associated protein 2.
Nicola Melillo, Daniel Scotcher, J. Gerry Kenna, Claudia Green, Catherine D. G. Hines, Iina Laitinen, Paul D. Hockings, Kayode Ogungbenro, Ebony R. Gunwhy, Steven Sourbron, John C. Waterton, Gunnar Schuetz, Aleksandra Galetin   +12 more
doaj   +1 more source

EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer

Advanced Science, Volume 13, Issue 12, 27 February 2026.
This schematic illustrates the mechanism of a senolytic strategy in endometrial cancer. EIF1AX facilitates the incorporation of DDX21 into nucleolar condensates, an event that suppresses rDNA transcription and induces cellular senescence. The compound 2,5‐MeC exploits this pathway by promoting EIF1AX nucleolar translocation and condensate formation ...
Chengyu Lv, Zihang Lin, Jiandong Sun, Yuhong Ye, Qibin Wu, Liangzhi Cai, Dabin Liu, Pengming Sun, Shie Wang   +8 more
wiley   +1 more source